Sabine D. Brookman-May, Professor of Urology at Universität München, Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared a post on X:
“HER2 testing clearly matters in Bladder Cancer
The next challenge: HER2 and Nectin-4 expression overlap heavily in mUC and we urgently need smarter strategies to match the right ADC to the right biology rather than treating targets as interchangeable.”
Markus Eckstein, Managing Senior Physician, Advanced Clinician Scientist and Research Group Leader at University Hospital Erlangen, Board Member ESUP and Ex-Officio Board Member ESUR at European Association of Urology, shared this post, adding:
“Disitamab-Vedotin plus Toripalimab showed similar clinical efficacy in metastatic urothelial cancer patients compared to EVP.
- only in biomarker positive patients: Her2neu 1+-3+
- ORR in phase 1/2 trial in Her2 negative (0) patients is 0% – thus likely no major effect in Her2 negative patients.
Her2 testing has a clear impact on selecting patients best suited for anti-Her2 ADCs. But how do we select for best fit ADC if we consider that Her2neu and Nectin4 is high in the same Patient population?”
Title: Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study
Authors: Xieqiao Yan, Juan Li, Huayan Xu, Yiqiang Liu, Li Zhou, Siming Li, Xiaowen Wu, Bixia Tang, Zhihong Chi, Chuanliang Cui, Lu Si, Lili Mao, Bin Lian, Xuan Wang, Rong Duan, Caili Li, Jianmin Fang, Jun Guo, Xinan Sheng
You can read the full article in Med.
More posts featuring Sabine D. Brookman-May.